Condition: Parkinson Disease · Sponsor: Biohaven Therapeutics Ltd.
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.
This description comes directly from the study's public registry record.
Chief Medical Officer · 203-404-0410 · clinicaltrials@biohavenpharma.com
Always discuss trial participation with your own doctor first.
| Site-049 | Birmingham, Alabama, United States | Recruiting |
| Site-041 | Los Angeles, California, United States | Recruiting |
| Site-031 | Farmington, Connecticut, United States | Recruiting |
| Site-028 | New Haven, Connecticut, United States | Recruiting |
| Site-038 | Atlantis, Florida, United States | Recruiting |
| Site-017 | Boca Raton, Florida, United States | Recruiting |
| Site-051 | Maitland, Florida, United States | Recruiting |
| Site-027 | Chicago, Illinois, United States | Recruiting |
| Site-071 | Boston, Massachusetts, United States | Recruiting |
| Site-015 | Farmington Hills, Michigan, United States | Recruiting |
| Site-044 | Chesterfield, Missouri, United States | Recruiting |
| Site-005 | New York, New York, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06976268